Antaiwei Biopharma
安泰维生物医药
MedTech, BioTech & PharmaShenzhen · South (Guangdong · Hong Kong · Hainan)
Business focus
MedTech, BioTech & Pharma
Description
Shenzhen Antaiwei Biopharmaceutical (深圳安泰维生物医药) is a biopharmaceutical company developing antiviral drugs; its lead candidate SHEN26 (ATV014) is an orally administered RdRp inhibitor and a prodrug of the nucleoside analog GS-441524. SHEN26 has completed a randomized, placebo-controlled Phase II clinical trial for COVID-19 and demonstrated broad-spectrum activity against multiple coronavirus variants (including Beta, Delta, and Omicron), outperforming remdesivir and GS-441524 in preclinical studies.